Proximal Ventures raises debut fund to back startups bringing AI to drug development

Sahir Raoof, a former SignalFire investor and executive at two healthcare startups, has successfully raised $27.5 million for his debut venture capital fund, Proximal Ventures. Raoof's firm aims to back startups that leverage artificial intelligence (AI) to revolutionize drug development processes. Traditionally, pharmaceutical companies have outsourced various stages of drug development, such as synthesizing molecular compounds, manufacturing drugs at scale, and analyzing clinical trial data, to specialized service providers.

Raoof believes that AI has the potential to automate these tasks, making it possible for startups to offer such services at a lower cost and in a shorter timeframe. Proximal Ventures plans to invest in pre-seed and seed-stage startups, committing funds ranging from $500,000 to $1.5 million per company. The firm has already invested in six startups, including ChronicleBio, which utilizes AI to analyze biological and medical data for a better understanding of chronic diseases and potential treatments.

Prior to founding Proximal Ventures, Raoof held positions at SignalFire, Iterative Health, and Flatiron Health, demonstrating his expertise in the healthcare sector and his ability to attract limited partners and investors. Notable backers of Proximal Ventures include VC firms SignalFire and Kleiner Perkins, Bertelsmann Healthcare Investments, as well as individual investors Nan Li and Zavain Dar from Dimension Capital, and Amy Abernethy, co-founder of Highlander Health and former principal deputy commissioner of the FDA.

Abernethy praised Raoof's ability to build relationships and identify industry bottlenecks, which she believes will contribute to the success of Proximal Ventures and its investments.